Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2013-08-10

AUTHORS

Judith Neukirchen, Uwe Platzbecker, Katja Sockel, Antonis Tsamaloukas, Rainer Haas, Ulrich Germing

ABSTRACT

Immunosuppressive therapy is a therapeutic option for selected low-risk myelodysplastic syndromes (MDS) patients. Besides standard treatment protocols that include ATG and CSA, the humanized CD52 antibody alemtuzumab has been shown to have efficacy in MDS treatment. We report our experience with alemtuzumab in nine MDS RCMD patients. All patients had a hypocellular bone marrow with a blast count <5 % and were classified as intermediate-1 according to the IPSS. We found a response in five patients (60 %); three patients achieved a complete remission 3 and 6 months after the treatment with alemtuzumab, and two patients showed a haematological improvement. Alemtuzumab was administered in a 10-mg dosage for 10 days. Treatment was well tolerated, and no severe side effects were observed. We could confirm the finding that the alemtuzumab is effective and save selected MDS patients. Due to the promising results, further studies, especially with regard to long-term survival and risk of leucemic progression should be initiated. More... »

PAGES

65-69

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-013-1859-1

DOI

http://dx.doi.org/10.1007/s00277-013-1859-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046839559

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23934199


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Alemtuzumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, CD", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Component Transfusion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "CD52 Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Count", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA (Cytosine-5-)-Methyltransferases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA Methyltransferase 3A", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycoproteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppressive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Subcutaneous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myelodysplastic Syndromes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Remission Induction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neukirchen", 
        "givenName": "Judith", 
        "id": "sg:person.0643404664.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643404664.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany", 
          "id": "http://www.grid.ac/institutes/grid.412282.f", 
          "name": [
            "Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Platzbecker", 
        "givenName": "Uwe", 
        "id": "sg:person.0670313557.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670313557.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany", 
          "id": "http://www.grid.ac/institutes/grid.412282.f", 
          "name": [
            "Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sockel", 
        "givenName": "Katja", 
        "id": "sg:person.01040552530.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040552530.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Private Practice, Hilden, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Private Practice, Hilden, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tsamaloukas", 
        "givenName": "Antonis", 
        "id": "sg:person.01002544733.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002544733.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haas", 
        "givenName": "Rainer", 
        "id": "sg:person.01127414674.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Germing", 
        "givenName": "Ulrich", 
        "id": "sg:person.01362464041.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.onc.1210380", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035428201", 
          "https://doi.org/10.1038/sj.onc.1210380"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2011.44", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023546509", 
          "https://doi.org/10.1038/leu.2011.44"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2403239", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015449707", 
          "https://doi.org/10.1038/sj.leu.2403239"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2404747", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011177675", 
          "https://doi.org/10.1038/sj.leu.2404747"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-08-10", 
    "datePublishedReg": "2013-08-10", 
    "description": "Immunosuppressive therapy is a therapeutic option for selected low-risk myelodysplastic syndromes (MDS) patients. Besides standard treatment protocols that include ATG and CSA, the humanized CD52 antibody alemtuzumab has been shown to have efficacy in MDS treatment. We report our experience with alemtuzumab in nine MDS RCMD patients. All patients had a hypocellular bone marrow with a blast count <5\u00a0% and were classified as intermediate-1 according to the IPSS. We found a response in five patients (60\u00a0%); three patients achieved a complete remission 3 and 6\u00a0months after the treatment with alemtuzumab, and two patients showed a haematological improvement. Alemtuzumab was administered in a 10-mg dosage for 10\u00a0days. Treatment was well tolerated, and no severe side effects were observed. We could confirm the finding that the alemtuzumab is effective and save selected MDS patients. Due to the promising results, further studies, especially with regard to long-term survival and risk of leucemic progression should be initiated.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00277-013-1859-1", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1358129", 
        "issn": [
          "0939-5555", 
          "1432-0584"
        ], 
        "name": "Annals of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "93"
      }
    ], 
    "keywords": [
      "hypocellular bone marrow", 
      "bone marrow", 
      "low-risk myelodysplastic syndrome patients", 
      "CD52 antibody alemtuzumab", 
      "complete remission 3", 
      "myelodysplastic syndrome patients", 
      "standard treatment protocol", 
      "lower-risk MDS", 
      "severe side effects", 
      "long-term survival", 
      "RCMD patients", 
      "remission 3", 
      "alemtuzumab treatment", 
      "immunosuppressive therapy", 
      "blast count", 
      "haematological improvement", 
      "antibody alemtuzumab", 
      "therapeutic options", 
      "MDS patients", 
      "MDS treatment", 
      "syndrome patients", 
      "treatment protocol", 
      "alemtuzumab", 
      "side effects", 
      "patients", 
      "Further studies", 
      "treatment", 
      "marrow", 
      "real-life experience", 
      "IPSS", 
      "therapy", 
      "progression", 
      "months", 
      "efficacy", 
      "CsA", 
      "promising results", 
      "survival", 
      "risk", 
      "count", 
      "dosage", 
      "days", 
      "life experiences", 
      "options", 
      "experience", 
      "findings", 
      "response", 
      "study", 
      "protocol", 
      "MD", 
      "ATG", 
      "effect", 
      "improvement", 
      "regard", 
      "results"
    ], 
    "name": "Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow", 
    "pagination": "65-69", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046839559"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-013-1859-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23934199"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-013-1859-1", 
      "https://app.dimensions.ai/details/publication/pub.1046839559"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_587.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00277-013-1859-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-013-1859-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-013-1859-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-013-1859-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-013-1859-1'


 

This table displays all metadata directly associated to this object as RDF triples.

276 TRIPLES      21 PREDICATES      109 URIs      97 LITERALS      33 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-013-1859-1 schema:about N0f762be268c54091a682229d50634b53
2 N1025c114b0a547f1acd6850aed0a84f8
3 N1f318ca04a2c4c2faa82f9732a016a98
4 N316dabc7abea4dfdb25859c7ed149f8d
5 N3606f9deb7924a17a9f5937a74a8704b
6 N386b0903f7d94464958f1333747fde27
7 N3ca9c0809c2348e6b8065c0126e240b2
8 N3f75a2eb3c13462cade7f498d8fcf1d5
9 N3ff34ac9563a4e89ad68f0ace9b1e2dd
10 N428e62e390b94ab1ab74721b163aa77a
11 N4ab3a95f641842c7b8f040fcb0cd51ed
12 N4d672385d3bd41a498c6a932e785afa0
13 N53c655862a8a4acf85b42e6f5c800270
14 N57cc28aa2bb546a38ad03901bbe2af26
15 N6825822ceb3644e9b3ce5c3691412deb
16 N6a8684fe6f9940bb9a56668075db7926
17 N6ed5d53bc5d3429999bbbc8f91e5c4d0
18 N7daf004392674185ac89d97e878a6488
19 N8401ad6996c7486c9154a8b617457262
20 N8aa30da8b400479da5a0a2e2b41b7207
21 N9d235143d3164aeb8ad2792bef960b21
22 N9e74eb4e692844828999b6fd5ffd3b93
23 Na1132853ebaa443786ac5bc12bd303a0
24 Nbf95b8f6a18d4d66bf61929705ba8601
25 Ndf26a0a20a874664b2d7cee845cd453f
26 Ne7fd05b068f3444aa7576bfe543ffa4a
27 anzsrc-for:11
28 anzsrc-for:1103
29 schema:author N0ae2044e34544d6887df012cbd93e732
30 schema:citation sg:pub.10.1038/leu.2011.44
31 sg:pub.10.1038/sj.leu.2403239
32 sg:pub.10.1038/sj.leu.2404747
33 sg:pub.10.1038/sj.onc.1210380
34 schema:datePublished 2013-08-10
35 schema:datePublishedReg 2013-08-10
36 schema:description Immunosuppressive therapy is a therapeutic option for selected low-risk myelodysplastic syndromes (MDS) patients. Besides standard treatment protocols that include ATG and CSA, the humanized CD52 antibody alemtuzumab has been shown to have efficacy in MDS treatment. We report our experience with alemtuzumab in nine MDS RCMD patients. All patients had a hypocellular bone marrow with a blast count <5 % and were classified as intermediate-1 according to the IPSS. We found a response in five patients (60 %); three patients achieved a complete remission 3 and 6 months after the treatment with alemtuzumab, and two patients showed a haematological improvement. Alemtuzumab was administered in a 10-mg dosage for 10 days. Treatment was well tolerated, and no severe side effects were observed. We could confirm the finding that the alemtuzumab is effective and save selected MDS patients. Due to the promising results, further studies, especially with regard to long-term survival and risk of leucemic progression should be initiated.
37 schema:genre article
38 schema:isAccessibleForFree false
39 schema:isPartOf N52e9a2abccc34530ab55450603a337a9
40 N75877c56ef8b473e900332bb91604100
41 sg:journal.1358129
42 schema:keywords ATG
43 CD52 antibody alemtuzumab
44 CsA
45 Further studies
46 IPSS
47 MD
48 MDS patients
49 MDS treatment
50 RCMD patients
51 alemtuzumab
52 alemtuzumab treatment
53 antibody alemtuzumab
54 blast count
55 bone marrow
56 complete remission 3
57 count
58 days
59 dosage
60 effect
61 efficacy
62 experience
63 findings
64 haematological improvement
65 hypocellular bone marrow
66 immunosuppressive therapy
67 improvement
68 life experiences
69 long-term survival
70 low-risk myelodysplastic syndrome patients
71 lower-risk MDS
72 marrow
73 months
74 myelodysplastic syndrome patients
75 options
76 patients
77 progression
78 promising results
79 protocol
80 real-life experience
81 regard
82 remission 3
83 response
84 results
85 risk
86 severe side effects
87 side effects
88 standard treatment protocol
89 study
90 survival
91 syndrome patients
92 therapeutic options
93 therapy
94 treatment
95 treatment protocol
96 schema:name Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow
97 schema:pagination 65-69
98 schema:productId N7f789d6d48fc4850bdb9f554fd13440e
99 N9055b3616eab4d91aa0320d652f3bfd5
100 N945c80abf57643baa6664a4e2d7bc32b
101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046839559
102 https://doi.org/10.1007/s00277-013-1859-1
103 schema:sdDatePublished 2022-08-04T17:00
104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
105 schema:sdPublisher N61e9b7e97f834f52b2117bced9a4609f
106 schema:url https://doi.org/10.1007/s00277-013-1859-1
107 sgo:license sg:explorer/license/
108 sgo:sdDataset articles
109 rdf:type schema:ScholarlyArticle
110 N0ae2044e34544d6887df012cbd93e732 rdf:first sg:person.0643404664.08
111 rdf:rest N64b7a33090db45cea62e45a263d9b398
112 N0f762be268c54091a682229d50634b53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Aged, 80 and over
114 rdf:type schema:DefinedTerm
115 N1025c114b0a547f1acd6850aed0a84f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Cell Count
117 rdf:type schema:DefinedTerm
118 N1bea64d19d0947dfb37d3eb7b1088ae4 rdf:first sg:person.01362464041.20
119 rdf:rest rdf:nil
120 N1f318ca04a2c4c2faa82f9732a016a98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Injections, Intravenous
122 rdf:type schema:DefinedTerm
123 N316dabc7abea4dfdb25859c7ed149f8d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Immunosuppressive Agents
125 rdf:type schema:DefinedTerm
126 N3606f9deb7924a17a9f5937a74a8704b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Male
128 rdf:type schema:DefinedTerm
129 N386b0903f7d94464958f1333747fde27 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Combined Modality Therapy
131 rdf:type schema:DefinedTerm
132 N3ca9c0809c2348e6b8065c0126e240b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Humans
134 rdf:type schema:DefinedTerm
135 N3f75a2eb3c13462cade7f498d8fcf1d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Blood Component Transfusion
137 rdf:type schema:DefinedTerm
138 N3ff34ac9563a4e89ad68f0ace9b1e2dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Adult
140 rdf:type schema:DefinedTerm
141 N428e62e390b94ab1ab74721b163aa77a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Glycoproteins
143 rdf:type schema:DefinedTerm
144 N4ab3a95f641842c7b8f040fcb0cd51ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Female
146 rdf:type schema:DefinedTerm
147 N4d672385d3bd41a498c6a932e785afa0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Myelodysplastic Syndromes
149 rdf:type schema:DefinedTerm
150 N52e9a2abccc34530ab55450603a337a9 schema:issueNumber 1
151 rdf:type schema:PublicationIssue
152 N53c655862a8a4acf85b42e6f5c800270 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Middle Aged
154 rdf:type schema:DefinedTerm
155 N57cc28aa2bb546a38ad03901bbe2af26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Remission Induction
157 rdf:type schema:DefinedTerm
158 N61e9b7e97f834f52b2117bced9a4609f schema:name Springer Nature - SN SciGraph project
159 rdf:type schema:Organization
160 N64b7a33090db45cea62e45a263d9b398 rdf:first sg:person.0670313557.25
161 rdf:rest N8b85b70348664cc78a27e7b500d69622
162 N6825822ceb3644e9b3ce5c3691412deb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Bone Marrow
164 rdf:type schema:DefinedTerm
165 N6a8684fe6f9940bb9a56668075db7926 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Antigens, CD
167 rdf:type schema:DefinedTerm
168 N6ed5d53bc5d3429999bbbc8f91e5c4d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name DNA Methyltransferase 3A
170 rdf:type schema:DefinedTerm
171 N70bcc49a08d4484f81d8939f13976957 rdf:first sg:person.01127414674.14
172 rdf:rest N1bea64d19d0947dfb37d3eb7b1088ae4
173 N75877c56ef8b473e900332bb91604100 schema:volumeNumber 93
174 rdf:type schema:PublicationVolume
175 N7daf004392674185ac89d97e878a6488 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name CD52 Antigen
177 rdf:type schema:DefinedTerm
178 N7f789d6d48fc4850bdb9f554fd13440e schema:name pubmed_id
179 schema:value 23934199
180 rdf:type schema:PropertyValue
181 N8401ad6996c7486c9154a8b617457262 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Alemtuzumab
183 rdf:type schema:DefinedTerm
184 N8aa30da8b400479da5a0a2e2b41b7207 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Antigens, Neoplasm
186 rdf:type schema:DefinedTerm
187 N8b85b70348664cc78a27e7b500d69622 rdf:first sg:person.01040552530.23
188 rdf:rest Nb59534b446d846c88360f027b925d851
189 N9055b3616eab4d91aa0320d652f3bfd5 schema:name doi
190 schema:value 10.1007/s00277-013-1859-1
191 rdf:type schema:PropertyValue
192 N945c80abf57643baa6664a4e2d7bc32b schema:name dimensions_id
193 schema:value pub.1046839559
194 rdf:type schema:PropertyValue
195 N9d235143d3164aeb8ad2792bef960b21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Aged
197 rdf:type schema:DefinedTerm
198 N9e74eb4e692844828999b6fd5ffd3b93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Drug Evaluation
200 rdf:type schema:DefinedTerm
201 Na1132853ebaa443786ac5bc12bd303a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name DNA (Cytosine-5-)-Methyltransferases
203 rdf:type schema:DefinedTerm
204 Nb59534b446d846c88360f027b925d851 rdf:first sg:person.01002544733.03
205 rdf:rest N70bcc49a08d4484f81d8939f13976957
206 Nbf95b8f6a18d4d66bf61929705ba8601 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Antibodies, Monoclonal, Humanized
208 rdf:type schema:DefinedTerm
209 Ndf26a0a20a874664b2d7cee845cd453f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Injections, Subcutaneous
211 rdf:type schema:DefinedTerm
212 Ne7fd05b068f3444aa7576bfe543ffa4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Retrospective Studies
214 rdf:type schema:DefinedTerm
215 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
216 schema:name Medical and Health Sciences
217 rdf:type schema:DefinedTerm
218 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
219 schema:name Clinical Sciences
220 rdf:type schema:DefinedTerm
221 sg:journal.1358129 schema:issn 0939-5555
222 1432-0584
223 schema:name Annals of Hematology
224 schema:publisher Springer Nature
225 rdf:type schema:Periodical
226 sg:person.01002544733.03 schema:affiliation grid-institutes:None
227 schema:familyName Tsamaloukas
228 schema:givenName Antonis
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002544733.03
230 rdf:type schema:Person
231 sg:person.01040552530.23 schema:affiliation grid-institutes:grid.412282.f
232 schema:familyName Sockel
233 schema:givenName Katja
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040552530.23
235 rdf:type schema:Person
236 sg:person.01127414674.14 schema:affiliation grid-institutes:grid.411327.2
237 schema:familyName Haas
238 schema:givenName Rainer
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14
240 rdf:type schema:Person
241 sg:person.01362464041.20 schema:affiliation grid-institutes:grid.411327.2
242 schema:familyName Germing
243 schema:givenName Ulrich
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20
245 rdf:type schema:Person
246 sg:person.0643404664.08 schema:affiliation grid-institutes:grid.411327.2
247 schema:familyName Neukirchen
248 schema:givenName Judith
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643404664.08
250 rdf:type schema:Person
251 sg:person.0670313557.25 schema:affiliation grid-institutes:grid.412282.f
252 schema:familyName Platzbecker
253 schema:givenName Uwe
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670313557.25
255 rdf:type schema:Person
256 sg:pub.10.1038/leu.2011.44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023546509
257 https://doi.org/10.1038/leu.2011.44
258 rdf:type schema:CreativeWork
259 sg:pub.10.1038/sj.leu.2403239 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015449707
260 https://doi.org/10.1038/sj.leu.2403239
261 rdf:type schema:CreativeWork
262 sg:pub.10.1038/sj.leu.2404747 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011177675
263 https://doi.org/10.1038/sj.leu.2404747
264 rdf:type schema:CreativeWork
265 sg:pub.10.1038/sj.onc.1210380 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035428201
266 https://doi.org/10.1038/sj.onc.1210380
267 rdf:type schema:CreativeWork
268 grid-institutes:None schema:alternateName Private Practice, Hilden, Germany
269 schema:name Private Practice, Hilden, Germany
270 rdf:type schema:Organization
271 grid-institutes:grid.411327.2 schema:alternateName Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany
272 schema:name Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany
273 rdf:type schema:Organization
274 grid-institutes:grid.412282.f schema:alternateName Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany
275 schema:name Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany
276 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...